Published in Front Pharmacol on May 05, 2017
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev (2001) 36.00
AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem (2009) 23.19
The cancer genome. Nature (2009) 23.13
Regulation of cancer cell metabolism. Nat Rev Cancer (2011) 15.44
Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod (2012) 13.27
Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science (2009) 8.65
hERG potassium channels and cardiac arrhythmia. Nature (2006) 6.63
Cancer Statistics, 2017. CA Cancer J Clin (2017) 4.77
Natural products: a continuing source of novel drug leads. Biochim Biophys Acta (2013) 4.12
The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett (2005) 2.25
From traditional Chinese medicine to rational cancer therapy. Trends Mol Med (2007) 2.02
Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta (2007) 1.79
Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist Updat (2012) 1.53
Understanding polyspecificity of multidrug ABC transporters: closing in on the gaps in ABCB1. Trends Biochem Sci (2009) 1.46
Overcoming psychological barriers to good discovery decisions. Drug Discov Today (2010) 1.16
Automatic QSAR modeling of ADME properties: blood-brain barrier penetration and aqueous solubility. J Comput Aided Mol Des (2008) 1.07
The evolutionary role of secondary metabolites--a review. Gene (1992) 1.06
Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy. Ann Pharmacother (2004) 1.00
Reversal of P-glycoprotein-mediated multidrug resistance of human hepatic cancer cells by Astragaloside II. J Pharm Pharmacol (2012) 0.90
Neferine isolated from Nelumbo nucifera enhances anti-cancer activities in Hep3B cells: molecular mechanisms of cell cycle arrest, ER stress induced apoptosis and anti-angiogenic response. Phytomedicine (2013) 0.88
Multidrug resistance reversal in human gastric carcinoma cells by neferine. World J Gastroenterol (2004) 0.88
Neferine, an alkaloid from lotus seed embryo, inhibits human lung cancer cell growth by MAPK activation and cell cycle arrest. Biofactors (2013) 0.88
P-glycoprotein (ABCB1) modulates collateral sensitivity of a multidrug resistant cell line to verapamil. Arch Biochem Biophys (2009) 0.87
Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk (2013) 0.83
Neferine increases STI571 chemosensitivity via inhibition of P-gp expression in STI571-resistant K562 cells. Leuk Lymphoma (2011) 0.83
Making priors a priority. J Comput Aided Mol Des (2010) 0.82
Neferine induces autophagy of human ovarian cancer cells via p38 MAPK/ JNK activation. Tumour Biol (2016) 0.81
[Effect of different heating methods combined with neferine on the expressions of γH2AX and mdr-1/P-gp in MCF-7/Adr breast cancer cells]. Zhong Nan Da Xue Xue Bao Yi Xue Ban (2011) 0.81
Renal excretion of rhodamine 123, a P-glycoprotein substrate, in rats with glycerol-induced acute renal failure. J Pharm Pharmacol (1998) 0.80
Gaussian processes for classification: QSAR modeling of ADMET and target activity. J Chem Inf Model (2010) 0.80
A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia. Leuk Res (2005) 0.80
The ability of molecular docking to unravel the controversy and challenges related to P-glycoprotein--a well-known, yet poorly understood drug transporter. Invest New Drugs (2014) 0.80
[Effect of neferine combined with mdr-1shRNA on the expression of mdr-1/P-gp in K562/A02 cell line]. Zhong Nan Da Xue Xue Bao Yi Xue Ban (2010) 0.80
A Comprehensive Review on Chemical Profiling of Nelumbo Nucifera: Potential for Drug Development. Phytother Res (2016) 0.79
Cytotoxicity of a naturally occurring furoquinoline alkaloid and four acridone alkaloids towards multi-factorial drug-resistant cancer cells. Phytomedicine (2015) 0.79
Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure. Clin Lymphoma Myeloma (2009) 0.79
Activity of the dietary flavonoid, apigenin, against multidrug-resistant tumor cells as determined by pharmacogenomics and molecular docking. J Nutr Biochem (2014) 0.79
Alkaloid rich fraction from Nelumbo nucifera targets VSMC proliferation and migration to suppress restenosis in balloon-injured rat carotid artery. Atherosclerosis (2016) 0.79
Interactions of human P-glycoprotein transport substrates and inhibitors at the drug binding domain: Functional and molecular docking analyses. Biochem Pharmacol (2016) 0.78
[Effect of neferine on the chemotherapic sensitivity of STI 571 to K562/A02 cells]. Zhong Nan Da Xue Xue Bao Yi Xue Ban (2005) 0.77
Resistance mechanisms of cancer cells to the novel vacuolar H(+)-ATPase inhibitor archazolid B. Invest New Drugs (2014) 0.77
Understanding the role of tariquidar, a potent Pgp inhibitor, in combination trials with cytotoxic drugs: What is missing? Cancer Chemother Pharmacol (2016) 0.77
Synergistic effect of hyperthermia and neferine on reverse multidrug resistance in adriamycin-resistant SGC7901/ADM gastric cancer cells. J Huazhong Univ Sci Technolog Med Sci (2011) 0.76
Cytotoxicity of the indole alkaloid reserpine from Rauwolfia serpentina against drug-resistant tumor cells. Phytomedicine (2015) 0.76
Nitensidine A, a guanidine alkaloid from Pterogyne nitens, is a novel substrate for human ABC transporter ABCB1. Phytomedicine (2013) 0.76
Specificity in the interaction of natural products with their target proteins--a biochemical and structural insight. Mini Rev Med Chem (2010) 0.75